We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Verona Pharma plc ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Merck announced Wednesday it will acquire UK-based Verona Pharma for approximately $10 billion, deepening its commitment to ...